NO955047D0 - Sekundære aminer som antidiabetiske og antifedme-midler - Google Patents

Sekundære aminer som antidiabetiske og antifedme-midler

Info

Publication number
NO955047D0
NO955047D0 NO955047A NO955047A NO955047D0 NO 955047 D0 NO955047 D0 NO 955047D0 NO 955047 A NO955047 A NO 955047A NO 955047 A NO955047 A NO 955047A NO 955047 D0 NO955047 D0 NO 955047D0
Authority
NO
Norway
Prior art keywords
pct
antidiabetic
date dec
secondary amines
obesity agents
Prior art date
Application number
NO955047A
Other languages
English (en)
Other versions
NO955047L (no
Inventor
Robert L Dow
Stephen W Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO955047L publication Critical patent/NO955047L/no
Publication of NO955047D0 publication Critical patent/NO955047D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO955047A 1993-06-14 1995-12-13 Sekundære aminer som antidiabetiske og antifedme-midler NO955047D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7602693A 1993-06-14 1993-06-14
PCT/IB1994/000117 WO1994029290A1 (en) 1993-06-14 1994-05-20 Secondary amines as antidiabetic and antiobesity agents

Publications (2)

Publication Number Publication Date
NO955047L NO955047L (no) 1995-12-13
NO955047D0 true NO955047D0 (no) 1995-12-13

Family

ID=22129472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955047A NO955047D0 (no) 1993-06-14 1995-12-13 Sekundære aminer som antidiabetiske og antifedme-midler

Country Status (22)

Country Link
US (1) US5767133A (no)
EP (1) EP0703911B1 (no)
JP (1) JPH08506348A (no)
KR (1) KR960703120A (no)
CN (1) CN1129443A (no)
AT (1) ATE154935T1 (no)
AU (1) AU675536B2 (no)
BR (1) BR9406823A (no)
CA (1) CA2164009A1 (no)
CZ (1) CZ327795A3 (no)
DE (1) DE69404039T2 (no)
DK (1) DK0703911T3 (no)
ES (1) ES2104383T3 (no)
FI (1) FI942791A (no)
GR (1) GR3024134T3 (no)
HU (1) HUT70844A (no)
IL (1) IL109904A0 (no)
NO (1) NO955047D0 (no)
NZ (1) NZ265692A (no)
PL (1) PL312005A1 (no)
WO (1) WO1994029290A1 (no)
ZA (1) ZA944139B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541197A (en) * 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
JPH11504648A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作動性アゴニスト
WO1996035671A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
GB2305665A (en) * 1995-09-26 1997-04-16 Merck & Co Inc Selective ß3 agonists for the treatment of diabetes aand obesity
CA2234081A1 (en) * 1995-10-31 1997-05-09 Pfizer Inc. Processes and intermediates for preparing 1-(2-[2-isoxazol-3-ylbenzofuran-5-yloxy]ethylamino)-3-phenoxy-2(s)-ol
CA2242351C (en) * 1996-01-10 2003-03-11 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US6031105A (en) * 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
US6008361A (en) * 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US5859044A (en) * 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
ATE319687T1 (de) * 1996-11-14 2006-03-15 Pfizer Verfahren zur herstellung von substituierten pyridinen
EP0842924B1 (en) * 1996-11-14 2003-08-20 Pfizer Inc. Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists
AU6852898A (en) * 1997-04-17 1998-11-11 Takeda Chemical Industries Ltd. Thermogenic composition and benzazepine thermogenics
DE997458T1 (de) 1997-07-03 2001-03-01 Asahi Chemical Ind Tricyclische verbindungen mit gesättigten ringen und diese enthaltende medizinische zubereitungen
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6469031B1 (en) 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6051586A (en) * 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
ID26524A (id) * 1997-12-19 2001-01-11 Bayer Ag Turunan-turunan kroman tersubstitusi karboksil bermanfaat sebagai agonis beta-3 adrenoreseptor
US6121271A (en) * 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
EP1077968A1 (en) * 1998-05-12 2001-02-28 American Home Products Corporation Naphtho[2,3-b]heteroar-4-yl derivatives
JP2002535396A (ja) * 1999-01-27 2002-10-22 イーライ・リリー・アンド・カンパニー セロトニン(5−ht(2c))アゴニストとしてのアミノアルキルベンゾフラン類
US7045545B1 (en) 1999-01-27 2006-05-16 Eli Lilly And Company Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
DE19932314A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuranderivate
EP1238973A4 (en) * 1999-12-16 2003-01-22 Asahi Chemical Ind NEW SUBSTITUTED TRICYCLIC COMPOUNDS
CN1430603A (zh) * 2000-04-28 2003-07-16 旭化成株式会社 新型双环化合物
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
WO2002100850A1 (fr) * 2001-06-08 2002-12-19 Kuraray Co., Ltd. Procedes de preparation de composes heterocycliques
KR100816527B1 (ko) * 2001-09-12 2008-04-10 한국화학연구원 페닐테트라졸 유도체로 치환된 β-아미노알코올 화합물
PT1447400E (pt) * 2001-10-25 2008-12-19 Asahi Kasei Pharma Corp Composto bicíclico
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
MXPA04008298A (es) * 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
US6844362B2 (en) 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
PL376396A1 (en) * 2002-10-11 2005-12-27 Pfizer Inc. Indole derivatives as beta-2 agonists
EP1407769A1 (en) * 2002-10-11 2004-04-14 Pfizer Limited Indole derivatives as beta-2 agonists
WO2004092131A1 (en) * 2003-01-06 2004-10-28 Eli Lilly And Company Indole derivatives as ppar modulators
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
CA2523253C (en) 2003-05-09 2010-06-22 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
BRPI0912267A2 (pt) 2008-05-23 2015-10-13 Amira Pharmaceuticals Inc sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
KR20110050734A (ko) 2008-10-09 2011-05-16 아사히 가세이 파마 가부시키가이샤 인다졸 화합물
CA2737349A1 (en) * 2008-10-09 2010-04-09 Asahi Kasei Pharma Corporation Indazole derivatives
US20100222404A1 (en) * 2008-11-04 2010-09-02 Asahi Kasei Pharma Corporation Indazole derivative dihydrochloride
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
EP2563123B1 (en) * 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
MX2022015613A (es) 2020-06-08 2023-04-04 Tactogen Inc Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268960A (en) * 1969-09-18 1972-03-29 Sandoz Ltd Indole derivatives
US3699123A (en) * 1970-03-24 1972-10-17 Sandoz Ltd 4-(3-amino-2-hydroxy-propoxy) indole derivatives
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
ATE1899T1 (de) * 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
EP0025331B1 (en) * 1979-09-06 1983-03-02 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3070865D1 (en) * 1979-11-15 1985-08-14 Beecham Group Plc Secondary ethanol amines, their preparation and their use in pharmaceutical compositions
CA1175851A (en) * 1980-09-26 1984-10-09 Beecham Group Limited Secondary amines
GR75101B (no) * 1980-10-23 1984-07-13 Pfizer
DE3169094D1 (en) * 1980-11-20 1985-03-28 Beecham Group Plc Secondary amines
FR2523964B1 (fr) * 1982-03-23 1985-09-27 Sanofi Sa Nouveaux derives de la tryptamine actifs notamment sur le systeme cardiovasculaire et procede pour leur preparation
JPS60202872A (ja) * 1984-03-27 1985-10-14 Kaken Pharmaceut Co Ltd ベンゾフラン誘導体、その製法およびそれを有効成分とする降圧剤
US4882433A (en) * 1985-10-30 1989-11-21 The Upjohn Company 3'-pyridinylalkylinden- and 3'-pyridinylalkylindol-2-carboxylic acids and analogs
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4886814A (en) * 1986-03-13 1989-12-12 Dr. Karl Thomas Gmbh Substituted thiazoles and oxazoles and 2-hydroxy-morpholines
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8925032D0 (en) * 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) * 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
US5106867A (en) * 1990-05-04 1992-04-21 American Cyanamid Company Method of increasing lean meat in edible animals
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd 2−アルキルアミノ−1−フェニルエタノール誘導体

Also Published As

Publication number Publication date
HU9401761D0 (en) 1994-09-28
GR3024134T3 (en) 1997-10-31
PL312005A1 (en) 1996-04-01
EP0703911B1 (en) 1997-07-02
NO955047L (no) 1995-12-13
FI942791A (fi) 1994-12-15
DE69404039T2 (de) 1997-10-16
HUT70844A (en) 1995-11-28
DK0703911T3 (da) 1997-10-06
ATE154935T1 (de) 1997-07-15
WO1994029290A1 (en) 1994-12-22
CN1129443A (zh) 1996-08-21
FI942791A0 (fi) 1994-06-13
EP0703911A1 (en) 1996-04-03
CA2164009A1 (en) 1994-12-22
ZA944139B (en) 1995-12-13
AU6687094A (en) 1995-01-03
ES2104383T3 (es) 1997-10-01
JPH08506348A (ja) 1996-07-09
NZ265692A (en) 1997-02-24
IL109904A0 (en) 1994-10-07
DE69404039D1 (de) 1997-08-07
US5767133A (en) 1998-06-16
BR9406823A (pt) 1996-03-26
CZ327795A3 (en) 1996-08-14
KR960703120A (ko) 1996-06-19
AU675536B2 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
NO955047D0 (no) Sekundære aminer som antidiabetiske og antifedme-midler
TR27835A (tr) Sübstitüe edilmis azadiokzasikloalkenler.
MX9702601A (es) AGONISTAS beta-ADRENERGICOS HETEROCICLICOS.
NO952321D0 (no) Polypeptid, samt anti-HIV-preparat fremstilt fra dette
PL320064A1 (en) Application of dioxomorpholines for fighting against endoparasites, novel dioxomorphoines and method of obtaining them
BR9406362A (pt) Composto,processo para a preparação do mesmo e composição anti-nuclear
ES2131528T3 (es) Nuevos polipeptidos y su uso.
NO972623D0 (no) Framasöytisk blanding omfattende lamotrigin
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
IL108288A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
TW261605B (no)
DE69109293T2 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
DK0731801T3 (da) Substituerede aminoaylkylaminopyridiner
FR2700116B1 (fr) Application d'anticonvulsivants comme radioprotecteurs.
MX9705815A (es) AGONISTAS beta-ADRENERGICOS.